HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

James M Downey Selected Research

5-hydroxydecanoic acid

4/2007The pH hypothesis of postconditioning: staccato reperfusion reintroduces oxygen and perpetuates myocardial acidosis.
8/2004Exogenous NO triggers preconditioning via a cGMP- and mitoKATP-dependent mechanism.
9/2003P1075 opens mitochondrial K(ATP) channels and generates reactive oxygen species resulting in cardioprotection of rabbit hearts.
8/2002The relative order of mK(ATP) channels, free radicals and p38 MAPK in preconditioning's protective pathway in rat heart.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


James M Downey Research Topics

Disease

59Infarction (Infarctions)
01/2020 - 01/2002
36Ischemia
11/2021 - 01/2002
13Myocardial Infarction
10/2018 - 05/2002
7Reperfusion Injury
11/2021 - 11/2003
6Coronary Occlusion
10/2013 - 09/2004
5Thrombosis (Thrombus)
01/2020 - 05/2013
5Hypothermia
03/2014 - 12/2010
4Myocardial Ischemia (Ischemic Heart Diseases)
01/2016 - 04/2004
3Necrosis
01/2016 - 03/2011
3Acidosis
03/2011 - 04/2007
2Inflammation (Inflammations)
11/2021 - 04/2010
2Heart Failure
01/2020 - 10/2018
2Acute Coronary Syndrome
04/2015 - 03/2014
1Hemorrhage
01/2020
1ST Elevation Myocardial Infarction
01/2019
1No-Reflow Phenomenon
11/2017

Drug/Important Bio-Agent (IBA)

12Adenosine (Adenocard)FDA LinkGeneric
01/2019 - 01/2002
10cangrelorIBA
01/2020 - 04/2013
9Adenosine Triphosphate (ATP)IBA
01/2016 - 08/2002
8Purinergic P1 Receptors (Adenosine Receptor)IBA
06/2012 - 03/2004
8triphenyltetrazoliumIBA
09/2008 - 09/2002
6Phosphotransferases (Kinase)IBA
07/2011 - 01/2005
5Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA
01/2019 - 05/2013
5Purinergic P2Y Receptor AntagonistsIBA
10/2018 - 03/2014
5WortmanninIBA
10/2013 - 02/2003
5chelerythrineIBA
10/2013 - 05/2006
5BradykininIBA
03/2008 - 03/2004
4Proteins (Proteins, Gene)FDA Link
11/2021 - 03/2004
4TicagrelorIBA
01/2019 - 10/2013
4BuffersIBA
01/2019 - 08/2002
4Opioid Analgesics (Opioids)IBA
01/2016 - 03/2004
4Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA
05/2012 - 07/2006
4BAY 60-6583IBA
05/2011 - 09/2007
4Cyclic GMP-Dependent Protein Kinases (Protein Kinase G)IBA
07/2009 - 08/2004
4mitochondrial K(ATP) channelIBA
07/2009 - 05/2002
4Adenosine-5'-(N-ethylcarboxamide) (NECA)IBA
09/2007 - 03/2004
45-hydroxydecanoic acidIBA
04/2007 - 08/2002
4Acetylcholine (Acetylcholine Chloride)FDA Link
04/2005 - 08/2002
3cariporideIBA
03/2014 - 10/2002
3Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA
05/2012 - 07/2006
31- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA
03/2011 - 04/2007
3SB 216763IBA
12/2010 - 07/2006
3NG-Nitroarginine Methyl Ester (L-NAME)IBA
12/2010 - 01/2006
3Oxygen (Dioxygen)IBA
09/2008 - 04/2007
3Mitochondrial Permeability Transition PoreIBA
09/2008 - 07/2006
3Free Radical ScavengersIBA
07/2008 - 08/2002
3Reactive Oxygen Species (Oxygen Radicals)IBA
04/2007 - 08/2002
3OxadiazolesIBA
07/2006 - 08/2004
3Ethanol (Ethyl Alcohol)IBA
04/2004 - 05/2002
2Phosphates (Orthophosphate)IBA
11/2021 - 01/2019
2Crystalloid SolutionsIBA
01/2019 - 12/2003
2Purinergic P1 Receptor AntagonistsIBA
01/2019 - 06/2012
2Clopidogrel (Plavix)FDA Link
01/2019 - 05/2013
2belnacasanIBA
10/2018 - 11/2017
2interleukin-1beta-converting enzyme inhibitorIBA
10/2018 - 11/2017
2Peptides (Polypeptides)IBA
11/2017 - 12/2003
2Opioid Receptors (Opioid Receptor)IBA
01/2016 - 06/2012
2LigandsIBA
01/2016 - 07/2008
2Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA
10/2013 - 01/2005
2FluorocarbonsIBA
06/2012 - 02/2007
2Theophylline (Theon)FDA LinkGeneric
06/2012 - 01/2005
2Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
05/2011 - 03/2006
2Soluble Guanylyl CyclaseIBA
12/2010 - 07/2006
2N- (4- cyanophenyl)- 2- (4- (2,3,6,7- tetrahydro- 2,6- dioxo- 1,3- dipropyl- 1H- purin- 8- yl)- phenoxy)acetamideIBA
09/2008 - 05/2006
2Protein Kinase CIBA
09/2008 - 04/2007
2Glycine (Aminoacetic Acid)FDA LinkGeneric
07/2008 - 04/2007
2AutacoidsIBA
03/2008 - 10/2003
2Leucine-2-Alanine Enkephalin (Enkephalin, Leucine 2 Alanine)IBA
04/2007 - 03/2004
2Nitric Oxide (Nitrogen Monoxide)FDA Link
05/2006 - 09/2004
2Guanylate Cyclase (Guanylyl Cyclase)IBA
01/2005 - 08/2004
2Potassium Channels (Potassium Channel)IBA
12/2003 - 08/2002
24- (7- ((2- 3- chloro- 2- thienyl)- 1- methyl- propylamino)- 3H- imidazo(4,5- b)pyridyl- 3- yl)cyclopentane carboxamideIBA
11/2003 - 10/2002
2Diazoxide (Hyperstat)FDA Link
08/2002 - 05/2002
1Purinergic P2X7 ReceptorsIBA
11/2021
1Toll-Like Receptors (Toll-Like Receptor)IBA
11/2021
1Pyruvic Acid (Pyruvate)IBA
11/2021
1MicroRNAs (MicroRNA)IBA
11/2021
1Oxidoreductases (Dehydrogenase)IBA
11/2021
1Caspase 1 (ICE Protease)IBA
11/2021
1EnzymesIBA
11/2021
1Adrenergic Receptors (Adrenergic Receptor)IBA
11/2021
1InterleukinsIBA
11/2021
1Toll-Like Receptor AgonistsIBA
11/2021
1InflammasomesIBA
11/2021
1Platelet Activating FactorIBA
01/2019
1Protect-ItIBA
01/2019
1CytokinesIBA
01/2019
1ProdrugsIBA
10/2018
1Pharmaceutical PreparationsIBA
10/2018
1Coloring Agents (Dyes)IBA
11/2017
1Cannabinoid Receptor AgonistsIBA
01/2016
1CannabinoidsIBA
01/2016
1Cannabinoid Receptors (Cannabinoid Receptor)IBA
01/2016
1Deoxyribonucleases (DNase)FDA Link
03/2015

Therapy/Procedure

10Ischemic Postconditioning
11/2017 - 05/2006
6Therapeutics
11/2017 - 01/2008
3Stents
01/2020 - 05/2013
2Microspheres (Microsphere)
11/2017 - 07/2008
2Liquid Ventilation
06/2012 - 02/2007
1Coronary Artery Bypass (Coronary Artery Bypass Surgery)
01/2020